{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:47:00Z","timestamp":1781542020072,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Young and middle-aged topics in South Anhui Medical College","award":["WK2022F01 and WK2022F09"],"award-info":[{"award-number":["WK2022F01 and WK2022F09"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cutaneous melanoma (CM) has an overall poor prognosis due to a high rate of metastasis. This study aimed to explore the role of hypoxia-related genes (HRGs) in CM.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We first used on-negative matrix factorization consensus clustering (NMF) to cluster CM samples and preliminarily analyzed the relationship of HRGs to CM prognosis and immune cell infiltration. Subsequently, we identified prognostic-related hub genes by univariate COX regression analysis and the least absolute shrinkage and selection operator (LASSO) and constructed a prognostic model. Finally, we calculated a risk score for patients with CM and investigated the relationship between the risk score and potential surrogate markers of response to immune checkpoint inhibitors (ICIs), such as TMB, IPS values, and TIDE scores.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Through NMF clustering, we identified high expression of HRGs as a risk factor for the prognosis of CM patients, and at the same time, increased expression of HRGs also indicated a poorer immune microenvironment. Subsequently, we identified eight gene signatures (FBP1, NDRG1, GPI, IER3, B4GALNT2, BGN, PKP1, and EDN2) by LASSO regression analysis and constructed a prognostic model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study identifies the prognostic significance of hypoxia-related genes in melanoma and shows a novel eight-gene signature to predict the potential efficacy of ICIs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12920-023-01587-8","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T11:02:24Z","timestamp":1688814144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Explore the impact of hypoxia-related genes (HRGs) in Cutaneous melanoma"],"prefix":"10.1186","volume":"16","author":[{"given":"Guolin","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiya","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,8]]},"reference":[{"key":"1587_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/ITT.S134842","volume":"7","author":"B Domingues","year":"2018","unstructured":"Domingues B, Lopes JM, Soares P, Populo H. Melanoma treatment in review. Immunotargets Ther. 2018;7:35\u201349.","journal-title":"Immunotargets Ther"},{"key":"1587_CR2","doi-asserted-by":"publisher","unstructured":"Brunsgaard E, Wu YP, Grossman D. Melanoma in Skin of Color: Part I. Epidemiology and clinical presentation. J Am Acad Dermatol. 2022. https:\/\/doi.org\/10.1016\/j.jaad.2022.04.056.","DOI":"10.1016\/j.jaad.2022.04.056"},{"issue":"4","key":"1587_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"4","key":"1587_CR4","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","volume":"21","author":"GT Gibney","year":"2015","unstructured":"Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21(4):712\u201320.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1587_CR5","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41467-017-02289-3","volume":"8","author":"M Schelker","year":"2017","unstructured":"Schelker M, Feau S, Du J, Ranu N, Klipp E, MacBeath G, et al. Estimation of immune cell content in tumour tissue using single-cell RNA-seq data. Nat Commun. 2017;8(1):2032.","journal-title":"Nat Commun"},{"key":"1587_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3389\/fonc.2018.00284","volume":"8","author":"B Wegiel","year":"2018","unstructured":"Wegiel B, Vuerich M, Daneshmandi S, Seth P. Metabolic switch in the tumor microenvironment determines immune responses to anti-cancer therapy. Front Oncol. 2018;8:284.","journal-title":"Front Oncol"},{"issue":"3","key":"1587_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211\u20138.","journal-title":"Trends Biochem Sci"},{"issue":"46","key":"1587_CR8","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.3748\/wjg.v16.i46.5874","volume":"16","author":"JL Chen","year":"2010","unstructured":"Chen JL, Tang HQ, Hu JD, Fan J, Hong J, Gu JZ. Metabolomics of gastric cancer metastasis detected by gas chromatography and mass spectrometry. World J Gastroenterol. 2010;16(46):5874\u201380.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"1587_CR9","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1089\/ars.2013.5378","volume":"21","author":"JC Walsh","year":"2014","unstructured":"Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 2014;21(10):1516\u201354.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"1587_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"X Jing","year":"2019","unstructured":"Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157.","journal-title":"Mol Cancer"},{"issue":"12","key":"1587_CR11","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1073\/pnas.0308531101","volume":"101","author":"JP Brunet","year":"2004","unstructured":"Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A. 2004;101(12):4164\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1587_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/1471-2105-11-367","volume":"11","author":"R Gaujoux","year":"2010","unstructured":"Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics. 2010;11:367.","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"1587_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218.","journal-title":"Genome Biol"},{"issue":"1","key":"1587_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248\u201362.","journal-title":"Cell Rep"},{"issue":"10","key":"1587_CR15","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138.","journal-title":"Nat Med"},{"issue":"3","key":"1587_CR16","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/SLA.0000000000002116","volume":"267","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Zhang Q, Hu Y, Li T, Yu J, Zhao L, et al. ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer. Ann Surg. 2018;267(3):504\u201313.","journal-title":"Ann Surg"},{"issue":"1","key":"1587_CR17","doi-asserted-by":"publisher","first-page":"152729","DOI":"10.1016\/j.prp.2019.152729","volume":"216","author":"PI Ribeiro Franco","year":"2020","unstructured":"Ribeiro Franco PI, Rodrigues AP, de Menezes LB, Pacheco MM. Tumor microenvironment components: allies of cancer progression. Pathol Res Pract. 2020;216(1):152729.","journal-title":"Pathol Res Pract"},{"issue":"11","key":"1587_CR18","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1587_CR19","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3390\/cancers13030558","volume":"13","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Cancers (Basel). 2021;13(3):558.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1587_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.canlet.2015.07.044","volume":"380","author":"Y Sun","year":"2016","unstructured":"Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett. 2016;380(1):205\u201315.","journal-title":"Cancer Lett"},{"issue":"4","key":"1587_CR21","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/ijms20040840","volume":"20","author":"C Roma-Rodrigues","year":"2019","unstructured":"Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting Tumor Microenvironment for Cancer Therapy. Int J Mol Sci. 2019;20(4):840.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1587_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40164-022-00297-8","volume":"11","author":"Z Liu","year":"2022","unstructured":"Liu Z, Yu X, Xu L, Li Y, Zeng C. Current insight into the regulation of PD-L1 in cancer. Exp Hematol Oncol. 2022;11(1):44.","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"1587_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1039\/D0MO00159G","volume":"17","author":"Y Shou","year":"2021","unstructured":"Shou Y, Yang L, Yang Y, Zhu X, Li F, Xu J. Determination of hypoxia signature to predict prognosis and the tumor immune microenvironment in melanoma. Mol Omics. 2021;17(2):307\u201316.","journal-title":"Mol Omics"},{"key":"1587_CR24","doi-asserted-by":"publisher","first-page":"6686284","DOI":"10.1155\/2021\/6686284","volume":"2021","author":"LB Song","year":"2021","unstructured":"Song LB, Luan JC, Zhang QJ, Chen L, Wang HY, Cao XC, et al. The Identification and Validation of a Robust Immune-Associated Gene Signature in Cutaneous Melanoma. J Immunol Res. 2021;2021:6686284.","journal-title":"J Immunol Res"},{"key":"1587_CR25","doi-asserted-by":"publisher","first-page":"954039","DOI":"10.3389\/fimmu.2022.954039","volume":"13","author":"Z Gao","year":"2022","unstructured":"Gao Z, Wang L, Song Z, Ren M, Yang Y, Li J, et al. Intratumoral CD73: an immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts. Front Immunol. 2022;13:954039.","journal-title":"Front Immunol"},{"issue":"26","key":"1587_CR26","doi-asserted-by":"publisher","first-page":"42901","DOI":"10.18632\/oncotarget.17160","volume":"8","author":"H Andrlova","year":"2017","unstructured":"Andrlova H, Mastroianni J, Madl J, Kern JS, Melchinger W, Dierbach H, et al. Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-beta1 expression. Oncotarget. 2017;8(26):42901\u201316.","journal-title":"Oncotarget"},{"key":"1587_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2147\/IJGM.S338890","volume":"15","author":"CL Jia","year":"2022","unstructured":"Jia CL, Yang F, Li RN. Identification of Potential Core Genes Between Primary and Metastatic Malignant Melanoma and Analysis of Their Immune Correlation. Int J Gen Med. 2022;15:379\u201391.","journal-title":"Int J Gen Med"},{"key":"1587_CR28","doi-asserted-by":"publisher","first-page":"e12944","DOI":"10.7717\/peerj.12944","volume":"10","author":"FY He","year":"2022","unstructured":"He FY, Chen G, He RQ, Huang ZG, Li JD, Wu WZ, et al. Expression of IER3 in hepatocellular carcinoma: clinicopathology, prognosis, and potential regulatory pathways. PeerJ. 2022;10:e12944.","journal-title":"PeerJ"},{"issue":"2","key":"1587_CR29","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/ijlh.13749","volume":"44","author":"S Ke","year":"2022","unstructured":"Ke S, Zhang X, Xiang X, Lu Y, An H. IER3 (IEX-1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients. Int J Lab Hematol. 2022;44(2):342\u20138.","journal-title":"Int J Lab Hematol"},{"issue":"21","key":"1587_CR30","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.3390\/cancers13215273","volume":"13","author":"F Dall'Olio","year":"2021","unstructured":"Dall\u2019Olio F, Pucci M, Malagolini N. The Cancer-Associated Antigens Sialyl Lewis(a\/x) and Sd(a): Two Opposite Faces of Terminal Glycosylation. Cancers (Basel). 2021;13(21):5273.","journal-title":"Cancers (Basel)"},{"issue":"22","key":"1587_CR31","first-page":"22776","volume":"12","author":"Z Liu","year":"2020","unstructured":"Liu Z, Zhong J, Cai C, Lu J, Wu W, Zeng G. Immune-related biomarker risk score predicts prognosis in prostate cancer. Aging (Albany NY). 2020;12(22):22776\u201393.","journal-title":"Aging (Albany NY)"},{"key":"1587_CR32","doi-asserted-by":"publisher","first-page":"660242","DOI":"10.3389\/fonc.2021.660242","volume":"11","author":"X Wang","year":"2021","unstructured":"Wang X, Li C, Chen T, Li W, Zhang H, Zhang D, et al. Identification and validation of a five-gene signature associated with overall survival in breast cancer patients. Front Oncol. 2021;11:660242.","journal-title":"Front Oncol"},{"issue":"2","key":"1587_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.coi.2013.03.004","volume":"25","author":"H Angell","year":"2013","unstructured":"Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261\u20137.","journal-title":"Curr Opin Immunol"},{"key":"1587_CR34","doi-asserted-by":"publisher","first-page":"7362721","DOI":"10.1155\/2017\/7362721","volume":"2017","author":"FM Buonaguro","year":"2017","unstructured":"Buonaguro FM, Pauza CD, Tornesello ML, Hainaut P, Franco R, Tommasino M. Cancer diagnostic and predictive biomarkers 2016. Biomed Res Int. 2017;2017:7362721.","journal-title":"Biomed Res Int"},{"key":"1587_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coi.2015.11.009","volume":"39","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Dieu-Nosjean MC, Sautes-Fridman C, Fridman WH. Cancer immune contexture and immunotherapy. Curr Opin Immunol. 2016;39:7\u201313.","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"1587_CR36","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/CCO.0000000000000405","volume":"29","author":"IP Silva","year":"2017","unstructured":"Silva IP, Long GV. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice. Curr Opin Oncol. 2017;29(6):484\u201392.","journal-title":"Curr Opin Oncol"},{"issue":"23","key":"1587_CR37","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1158\/1078-0432.CCR-16-0066","volume":"22","author":"DA Braun","year":"2016","unstructured":"Braun DA, Burke KP, Van Allen EM. Genomic approaches to understanding response and resistance to immunotherapy. Clin Cancer Res. 2016;22(23):5642\u201350.","journal-title":"Clin Cancer Res"},{"issue":"7637","key":"1587_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"key":"1587_CR39","doi-asserted-by":"crossref","unstructured":"Guo X, Yu X, Zhang Y, Luo H, Huang R, Zeng Y, et al. A novel glycolysis-related signature for predicting the prognosis and immune infiltration of uveal melanoma. Ophthalmic Res. 2023;66(1):696\u2013709.","DOI":"10.1159\/000529818"},{"key":"1587_CR40","doi-asserted-by":"publisher","first-page":"998792","DOI":"10.3389\/fgene.2022.998792","volume":"13","author":"Y Gao","year":"2022","unstructured":"Gao Y, Hou Q, Guo R, Ying J, Xiong J, Jiang H. Effect of Sun exposure-induced ferroptosis mechanisms on pathology and potential biological processes of primary melanoma by microarray data analysis. Front Genet. 2022;13:998792.","journal-title":"Front Genet"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01587-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-023-01587-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01587-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T11:03:02Z","timestamp":1688814182000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-023-01587-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,8]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1587"],"URL":"https:\/\/doi.org\/10.1186\/s12920-023-01587-8","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,8]]},"assertion":[{"value":"15 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"160"}}